{'fraction_non_alphanumeric': 0.01790633608815427, 'fraction_numerical': 0.0013774104683195593, 'mean_word_length': 5.433628318584071, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metformin in ovarian cancer therapy: A discussion

Overweight and obesity are dramatically increasing worldwide. In addition to being the most important factor for the increase in diabetes prevalence, there is a growing evidence of obesity being also significantly associated with the risks and poor outcome in ovarian cancer (OVC). Metformin is the most widely used first-line type 2 diabetes drug, currently being studied for its association with the decreased risk of occurrence and better survival of OVC patients. In this review, we discussed the proposed mechanisms of metformin-exerted anticancer effects, as well as the preclinical and clinical data suggesting its beneficial effect against this devastating condition.